BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
Company to review BXCL502 and other potential emerging pipeline candidates
Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential treatment for chronic use
Related news for (BTAI)
- UPDATE — BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
- 24/7 Market News Snapshot 27 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)
- 24/7 Market News Snapshot 27 August, 2025 – BioXcel Therapeutics, Inc. Common Stock (NASDAQ:BTAI)
- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/27/25 06:00 AM